Skip to content
Screener

Operating Income at other companies

AbbVie logo
AbbVieABBV
$6.43B+31.4%
Bausch + Lomb logo
Bausch + LombBLCO
$83M+855%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$93.34M-46.0%
HRO
HarrowHROW
-$22.08M-96.6%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
-$97.38M-56.5%
Schering-Plough logo
Schering-PloughSGP
-$15.41M-108%

Segments

By segment

See full
Reportable Segment-$19.91M+10.3%

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.87B+63.9%
Enterprise value$2.75B+59.6%
P/S4.7×-1.2×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:25 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001819790-26-000064
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development31,01015,59453,36130,003
Selling, general and administrative150,697103,013287,126188,008
Total operating expenses193,820124,844361,996229,459
Loss from operations before other income (expense)(19,908)(22,184)(26,030)(48,464)
Other income (expense):
Interest income3,6984,2297,4207,683
Interest expense(2,156)(2,240)(4,284)(4,453)
Gain on exchange of long-term investments2,8122,812

Item 1. Financial Statements

FAQ

What is Tarsus Pharmaceuticals, Inc.'s operating income?
Tarsus Pharmaceuticals, Inc. (TARS) reported operating income of -$19.91M in Q2 2026.
How has Tarsus Pharmaceuticals, Inc.'s operating income changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s operating income increased by 10.3% year-over-year, from -$22.18M to -$19.91M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating income?
Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s operating income has grown at a 55.4% compound annual growth rate (CAGR), from -$12.16M to -$70.97M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude